# Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

> **NCT03724240** · PHASE3 · UNKNOWN · sponsor: **ASIT Biotech S.A.** · enrollment: 624 (estimated)

## Conditions studied

- Hay Fever

## Interventions

- **BIOLOGICAL:** Placebo solution
- **BIOLOGICAL:** gpASIT+TM

## Key facts

- **NCT ID:** NCT03724240
- **Lead sponsor:** ASIT Biotech S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-02
- **Primary completion:** 2019-09
- **Final completion:** 2019-12
- **Target enrollment:** 624 (ESTIMATED)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724240, "Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03724240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*